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 INTRODUCTION
 Transjugular intrahepatic portosystemic shunt (TIPS) is currently 
used for the treatment of complications of portal hypertension, 
mainly variceal rebleeding and refractory ascites ( 1–9 ). Th is pro-
cedure involves a major drawback: hepatic encephalopathy (HE). 
Th is complication has been reported in 30–55% ( 10–15 ) of cir-
rhotic patients within the fi rst year, and up to 10% of patients 
treated with a TIPS may experience a severe form of HE that is 
refractory to standard treatments and will need to be resolved 
by reducing the shunt diameter ( 13 ). Unfortunately, no pharma-
cological treatment has yet proved to be able to reduce the inci-
dence of post-TIPS HE. Th e only randomized controlled trial 
carried out with this aim failed to show any benefi cial eff ect of 
drugs commonly used in the treatment of HE ( 16 ). More recently, 
a randomized controlled trial was performed to assess the effi  cacy 
of polytetrafl uoroethylene-covered stents of diff erent diameters 
(10 vs. 8 mm) on the incidence of post-TIPS HE. Unfortunately, 
the trial was stopped because the stents with the smaller diameter 
were unable to control the complications of portal hypertension 
( 17 ). Th us, the selection of patients remains the only method to 
try to reduce the incidence of post-TIPS HE, and many studies 
have attempted to identify the predictors of this complication in 
order to select for TIPS only those patients with the lowest inci-
dence. Th e factors identifi ed as the most robust predictors of 
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post-TIPS HE were previous HE, age, a low porto-caval pressure 
gradient, and a high Child–Pugh score ( 13,18–20 ). Further factors 
were high creatinine levels ( 13 ) and low serum sodium concen-
tration ( 21 ). Despite the exclusion of patients with previous HE 
and advanced liver disease, the incidence of post-TIPS HE still 
remains fairly high ( 22 ); thus, other factors are involved.
 In cirrhotic patients without TIPS, the presence of subclinical 
cognitive impairment, also known as covert HE ( 23 ), has been 
shown to be a strong predictor of the occurrence of overt HE 
( 24 ). Correspondingly, alterations in psychometric performance 
detected in a TIPS candidate before the procedure may help iden-
tify the patients at risk of HE aft er the procedure. Actually, in our 
randomized controlled trial ( 16 ), post-TIPS HE developed more 
frequently in patients with an abnormal psychometric test (Trail 
Making Test A) before TIPS, and, more recently, Berlioux P.  et al. 
showed in 54 patients submitted to a TIPS that the incidence of HE 
increased in those with abnormal critical fl icker frequency before 
a TIPS ( 25 ). However, in both studies, the relationship between 
psychometric performance and post-TIPS HE was present only at 
the univariate analysis, and thus the role of cognitive impairment 
as a risk factor for HE aft er a TIPS remains uncertain.
 Th e aim of the present study was to establish whether pre-TIPS 
covert HE is an independent risk factor for the development of HE 
and whether the psychometric evaluation before a TIPS may be 
used for selecting patients in order to have the lowest rate of HE 
aft er a TIPS.
 METHODS
 From January 2011 to December 2014, all consecutive cirrhotic 
patients undergoing TIPS were considered eligible for the study. 
In our Center, exclusion criteria for TIPS placement are age >75 
years, bilirubin levels >5 mg/dl, creatinine levels >3 mg/dl, a seri-
ous cardiac or pulmonary dysfunction, a Child–Pugh’s score >11 
(except for patients who were candidates for early TIPS), a model 
end-stage liver disease score >18, the presence of portal throm-
bosis, a diagnosis of hepatic carcinoma, sepsis, and spontaneous 
bacterial peritonitis. Present HE or previous spontaneous/recur-
rent HE is also a contraindication to TIPS; however, patients with 
only one episode of HE precipitated by variceal bleeding and 
ameliorated aft er the bleeding was controlled are not excluded. 
Other exclusion criteria were alcohol/psychoactive drugs intake 
(positive alcoholaemia and/or benzodiazepines or opioid urine 
metabolites) at the moment of evaluation, unrelated neurologi-
cal disease including dementia (mini mental state <26), and lack 
of compliance with psychometric evaluation because of language 
barriers or reduced visual acuity.
 Th e purpose of the study, the enrollment, and the details of the 
TIPS operation were clearly explained to all the patients before 
obtaining their written informed consent. Th e “Sapienza” Univer-
sity of Rome Ethical Committee approved the collection of data of 
the patients for prognostic studies (Rif.1720/01.10.09).
 All TIPS procedures were carried out by the same radiology 
team, using polytetrafl uoroethylene-covered stents of 10 mm 
diameter. Th e anesthesiological procedure ( 4,26 ) and the technical 
details of TIPS with polytetrafl uoroethylene-covered stent-graft  
implantation were previously described ( 27,28 ). All the sub-
jects were evaluated and followed by the same medical team by a 
prospective protocolled diagnostic work-up and a surveillance 
strategy.
 Th e day before the procedure, a basal evaluation of HE, includ-
ing an examination and grading of the patients’ mental state, 
asterixis, and psychometric performance, as well as the determina-
tion of venous blood ammonia, were carried out. Th e evaluation of 
the degree of HE was based on the alteration of the patient’s mental 
state using modifi cations of the West Haven Criteria ( 29 ). Th e men-
tal state was assessed in each patient by the same investigator using 
standardized tests and questions, as previously described ( 30 ). All 
patients also underwent the psychometric HE score (PHES) bat-
tery of tests, including the digit-symbol-test, the trail-making-test 
A and B, the serial-dotting-test, and the line-tracing-test. Each 
test was scored against age and education-adjusted norms for the 
Italian population. Th e PHES is the sum of integer scores of each 
test computed from the adjusted Z-values, as follows: score=−3 for 
 Z ≤−3, score −2 for −3< Z ≤−2, score −1 for −2< Z ≤−1, score 0 for 
−1< Z <1, score 1 for  Z ≥1. Th e PHES ≤−4 was considered abnormal 
( 30 ). Blood samples from a peripheral vein were collected in iced 
tubes for the determination of ammonia, which was performed 
immediately aft er using the Ammonia Checker II (Menarini, Flor-
ence, Italy), as previously described ( 31 ).
 None of the patients received any pharmacological treatment to 
prevent the occurrence of HE. Aft er TIPS, the patients remained 
hospitalized for 1 week and then were followed up once a week 
in the outpatient department for the fi rst month. Th e patients 
were then seen every 3 months and also contacted by phone every 
month for the fi rst 6 months. Th ereaft er, the patients were seen 
every 6 months. Moreover, both the patients and their families 
were instructed about the importance of an immediate contact 
with the medical staff  should any alteration in their mental state 
occur between the scheduled visits. In particular, the family was 
instructed to refer the occurrence of lethargy, apathy, obvious per-
sonality changes, inappropriate behavior, or disorientation to time 
and space (corresponding to a grade-II alteration of the patients’ 
mental state). In this case, the HE evaluation, including the psy-
chometric performance, was repeated to confi rm and stage the 
degree of HE. A grade II HE or higher was considered an episode 
of overt HE ( 23 ), and the patients were censored as HE+ patients. 
Th e occurrence of a recurrent HE (defi ned as at least three epi-
sodes of non precipitant-induced severe encephalopathy requiring 
hospitalization in the last 3 months despite continuous treatment 
with non-absorbable disaccharides) or a persistent HE (defi ned 
as the presence of a continuously detectable altered mental state 
with further episodic deterioration despite protein restriction and 
treatment with non-absorbable disaccharides) was also recorded, 
and the patients were considered aff ected by refractory HE. Th ose 
patients with an overt episode of HE were then managed either as 
in- or outpatients, depending on the severity of the HE episode. 
Once developed, HE was treated with the oral administration of 
non-absorbable disaccharides or non-absorbable antibiotics. All 
potential HE precipitating events were treated and, when possi-
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ble, avoided. Th e patients’ outcomes considered for the statistical 
analysis were the fi rst episode of HE, liver transplantation (LT), 
and death.
 Statistical analysis
 Th e data are reported as mean±s.d. Comparisons between groups 
were performed by unpaired Student’s  t -test or  χ 2 -test. We esti-
mated the cumulative incidence of the fi rst episode of HE during 
the fi rst 6 months of follow up, taking into account the nature of 
the competing risks in the data (HE before LT, death, and LT are 
competing events). As the study is estimating outcomes other than 
all-cause mortality, a method based on multistate disease mod-
els was selected. Th e usual Cox regression model in this context 
might be severely biased ( 32 ) and the sub-distribution model of 
Fine and Gray was selected. Th e conditional sub-distribution haz-
ard at multivariate analysis was evaluated using the model of Fine 
and Gray ( 33 ). We therefore report on the sub-distribution haz-
ard ratios (sHRs) rather than the usual HR, but the former have 
similar interpretations to the latter. Th e factors associated with the 
development of HE were initially evaluated by univariate mod-
els (using univariate Fine and Gray models) and then included in 
a multivariate analysis (according to multivariate Fine and Gray 
models). Th e fi nal multivariate model was chosen in a forward 
manner by minimizing the Bayesian Information Criterion.
 In order to build a score for the prediction of HE post TIPS, 
we built an event-history analysis model allowing for competing 
risks, therefore predicting the risk of the event. Th e maximum 
likelihood coeffi  cients of the optimal model were used as weights 
for the new score. A time-dependent ROC curve ( 34 ) for censored 
data at 6 months of follow-up was estimated using the NN estima-
tion method, whereas signifi cance tests and confi dence intervals 
were assessed through the non-parametric bootstrap. Sensitivity, 
specifi city, positive predictive value, and negative predictive value 
were based on the estimated relative operating characteristic at 6 
months. Soft ware R version 3.0.2 (Stanford University, CA) was 
used for all computations.
 RESULTS
 Th e demographic, clinical, and biochemical characteristics of the 
patients are reported in  Table 1 .
 During the whole follow-up, 35 of the 82 (43%) patients devel-
oped at least one episode of overt HE. In 3 of them, HE persisted 
and was refractory to standard treatment, needing the reduction in 
the stent calibre to ameliorate. Th is procedure was carried out 5, 6, 
and 8 months aft er TIPS and led to the resolution of HE symptoms 
in all patients. During the whole follow-up, 13 patients died and 5 
were transplanted.
 Th e comparison between the 35 patients with overt HE and the 
47 patients who did not develop HE aft er a TIPS is reported in 
 Table 2 . At the time of the TIPS placement, there were no signifi -
cant diff erences between the two groups in gender, etiology and 
severity of liver disease (Child–Pugh and model end-stage liver 
disease score) and most biochemical parameters. However, age (55 
vs. 62 years) was signifi cantly higher and serum sodium (138 vs. 
135 mEq/ml) signifi cantly lower in patients with post-TIPS HE. 
Th e porto-systemic gradient measured immediately aft er the shunt 
opening was 6.9±3.9 in the HE patient group and 5.9±3.2 in the 
patients who did not develop HE aft er a TIPS (NS). In the group 
of patients with HE aft er a TIPS, there was a higher prevalence of 
patients in whom TIPS was indicated because of refractory ascites, 
but the diff erence did not reach statistical signifi cance ( P =0.08). As 
far as the pre-TIPS evaluation of the patients’ cognitive function 
is concerned, according to our exclusion criteria, no patients had 
signs of HE at inclusion and only a few of them (11 patients, 13%) 
experienced one episode of precipitated HE before a TIPS.
 Seventy-seven percent of the patients with post-TIPS HE were 
classifi ed as aff ected by covert HE before a TIPS according to the 
PHES evaluation. Th e corresponding fi gure in the group without 
HE was 32% and the diff erence was highly signifi cant ( P =0005). 
Th e cumulative incidence of HE aft er TIPS, taking into consid-
eration LT and death as risks competing with HE development, 
is reported in  Figure 1 . Th e diff erence in the incidence of post-
TIPS HE was highly signifi cant ( P =0.0003) among patients with 
or without covert HE detected by PHES before a TIPS. Th is diff er-
ence, however, was at the limit of statistical signifi cance, if only the 
37 patients operated because of variceal bleeding are considered 
(58 vs. 28%;  P =0.07), whereas it was highly signifi cant in the 45 
patients submitted to a TIPS because of refractory ascites (87 vs. 
36%;  P =0.0001). Moreover, all the 3 patients with refractory HE 
belonged to the group of ascitic patients.
 Table 1 .  Demographic and clinical characteristics of the patients 
included in the study 
  Patients ( n =82) 
 Sex (M/F)  57/25 
 Age (y)  57.9±10.1 (25–78) 
 Etiology (virus/alcohol/other)  34/29/19 
 MELD  11.4±3.3 (6–23) 
 Child–Pugh class (A/B/C)  17/53/12 
 Child–Pugh score  7.6±1.5 (5–11) 
 TIPS indication (bleeding/refractory ascites)  37/45 
 Previous HE (no/yes)  71/11 
 Covert HE (PHES ≤−4)(no/yes)  40/42 
 Bilirubin (mg/dl)  1.5±0.8 (0.5–4) 
 Albumin (g/dl)  3.3±0.5 (2.1–4.5) 
 INR  1.3±0.1 (0.9–1.9) 
 Sodium (mEq/l)  136.8±4.6 (124–145) 
 NH3 (microg/dl)  51.9±24.4 (10–146) 
 Gradient pre TIPS (mm Hg)  20.5±6.2 (11–41) 
 Gradient post TIPS (mm Hg)  6.3±3.5 (4–22) 
 F, female; HE, hepatic encephalopathy; INR, international normalized ratio; 
M, male; MELD, model end-stage liver disease; PHES, psychometric hepatic 
encephalopathy score; TIPS, transjugular intrahepatic portosystemic shunt; Y, years. 
 Mean±s.d. 
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 Age, severity of liver disease (Child–Pugh/model end-stage liver 
disease), TIPS indication (varices/ascites), and covert HE were 
included in the Fine and Gray multivariate model analysis. Age: 
(sHR 1.05, CI 1.02–1.08,  P =0.0022); Child–Pugh score: (sHR 1.29, 
CI 1.06–1.56,  P =0.0110); and covert HE: (sHR 3.16 CI: 1.43–6.99 
 P =0.0045) were independently associated with post-TIPS HE 
development. On the basis of these results, a model was developed 
as follows: Age/10+Child–Pugh score+4.88 if covert HE is present 
with an AUC of 0.75. With a cutoff  of 17, sensitivity was 0.77 (0.72–
0.82), specifi city 0.75 (0.70–0.80), PPV 0.64 (0.59–0.69), and NPV 
0.83 (0.79–0.87). If age and the Child–Pugh score are excluded and 
only the presence of covert HE before a TIPS is considered, the 
corresponding values are sensitivity 0.74 (0.69–0.79), specifi city 
0.63 (0.58–0.68), PPV 0.55 (0.50–0.60), and NPV 0.80 (0.76–0.84). 
Th e NPV was 0.78 (0.71–0.85) in the group of patients submit-
ted to TIPS to prevent variceal rebleeding and 0.88 (0.83–0.93) in 
patients operated on because of refractory ascites.
 DISCUSSION
 Th e identifi cation of the risk factors for the development of HE 
aft er a TIPS is a relevant problem. In fact, post-TIPS HE is very 
frequent and, although in a minority of patients, it may be persis-
tent and refractory to medical treatment, thus aff ecting deeply the 
patients’ quality of life. Th e problem is, in our opinion, particu-
larly relevant in patients submitted to a TIPS because of refrac-
tory ascites. In fact, at variance with the TIPS performed for the 
prevention of variceal rebleeding, which can be life saving and 
without therapeutic alternatives, a patient with refractory ascites 
may be treated with a TIPS or repeated large volume paracente-
sis with a fairly similar effi  cacy at least in terms of survival. Th e 
lack of preventive measures, whether pharmacological or based 
on the optimization of the porto-systemic gradient reached aft er 
the procedure, makes the optimal selection of patients particu-
larly crucial. Previous HE with the exception of that precipitated 
by variceal bleeding, especially if recidivant, aging and advanced 
liver failure are the most robust risk factors for post-TIPS HE ( 35 ), 
and today most protocols and clinical studies consider the pres-
ence of these factors as a contraindication to TIPS. Nevertheless, 
the incidence of post-TIPS HE continues to be regrettably high, 
suggesting that other factors may be important.
 Th e working hypothesis of the present paper was that the subclini-
cal cognitive impairment, also known as covert HE, may be a predic-
tive factor for overt HE development aft er a TIPS. Th is hypothesis 
is supported by the fact that covert HE is one of the strongest pre-
dictors of the occurrence of overt HE in the follow-up in cirrhotic 
 Table 2 .  Demographic and clinical characteristics of the patients 
with or without HE after TIPS placement 
  Post-TIPS hepatic encephalopathy  P  value 
  Absent ( n =47)  Present ( n =35)  
 Sex (M/F)  32/15  25/10  NS 
 Age (y)  54.8±10.4 
(25–77) 
 61.9±8.9 
(45–78) 
 0.001 
 Etiology (virus/
alcohol/other) 
 20/17/10  14/12/9  NS 
 MELD  10.8±3.6 (6–23)  11.7 ±3.6 
(6–18) 
 NS 
 Child–Pugh class 
(A/B/C) 
 13/29/5  4/24/7  NS 
 Child–Pugh score  7.4±1.4 (5–10)  7.9±1.5 (5–11)  NS 
 TIPS indication 
(bleeding/refractory 
ascites) 
 25/22  12/23  NS 
 Previous HE (no/yes)  43/4  28/7  NS 
 Covert HE (PHES 
≤−4) (no/yes) 
 32/15  8/27  <0.0005 
 Bilirubin (mg/dl)  1.4±0.8 
(0.5–3.8) 
 1.8±1.5 
(0.5–4.5) 
 NS 
 Albumin (g/dl)  3.4±0.5 
(2.1–4.3) 
 3.3±0.5 
(2.2–4.5) 
 NS 
 INR  1.3±0.17 
(1–1.9) 
 1.2±0.17 
(0.9–1.6) 
 NS 
 Sodium (mEq/l)  138±4.3 
(124–145) 
 135±4.9 
(125–143) 
 0.009 
 NH3 (microg/dl)  51±27 (10–146)  53±20 (10–85)  NS 
 Gradient before  20.5±5.8 
(11–36) 
 20.4±6.8 
(11–41) 
 NS 
 Gradient after  5.9±3.2 (4–11)  6.9±3.9 (3–22)  NS 
 F, female; HE, hepatic encephalopathy; INR, international normalized ratio; 
M, male; MELD, model end-stage liver disease; NS, not signifi cant; PHES, 
psychometric hepatic encephalopathy score; TIPS, transjugular intrahepatic 
portosystemic shunt; Y, years. 
 Mean±s.d. 
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 Figure 1 .  Cumulative incidence of HE post TIPS for patients with and 
without MHE, taking into account two additional competing risks: OLT and 
Death. HE, hepatic encephalopathy; MHE, minimal hepatic encephalopa-
thy; OLT, orthotopic liver transplantation; TIPS, transjugular intrahepatic 
portosystemic shunt. 
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of the tests included in the PHES, the standard for the identifi ca-
tion of patients aff ected by covert HE, as well as the critical fl icker 
frequency, was signifi cantly correlated with post-TIPS HE at least at 
univariate analysis. Our results support the hypothesis, as the inci-
dence of post-TIPS HE was signifi cantly diff erent among patients 
with or without covert HE before a TIPS. Our results are particu-
larly solid because they were obtained in a group of patients already 
selected for TIPS on the basis of the known risk factors for HE 
development (see inclusion criteria). Moreover, post-TIPS HE was 
detected using the PHES, which is considered the standard method 
( 23 ), and statistically analyzed taking into consideration the risks 
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